Steroid-induced skin atrophy

Signs and symptoms

Skin atrophy typically presents as thin, shiny skin. Wrinkling of the skin and erythema may also be observed. In lighter skin tones, erythema presents as bright red, while darker skin tones appear more dark brown.

Once atrophy develops, further and deeper topical steroid side effects may occur, such as telangiectasia, easy bruising, purpura, and striae.

Intralesional steroids may result in an indentation at the site of injection.

Diagnosis

Steroid-induced skin atrophy is a clinical diagnosis that is aided by patient history. A correlation between start of steroid application and presentation of side effects may be deduced. Key patient history features include amount of steroid applied, frequency and length of application, and location. An important distinction between a systemic versus external cause of skin conditions is symmetry and definition. Clues for an external cause include well-defined borders in the area of steroid application, as well as asymmetry. These physical findings support topical steroid etiology.

Treatment

The mainstay of steroid-induced skin atrophy treatment is immediate discontinuation of any further topical corticosteroid use. Protection and support of the impaired skin barrier is another priority. This can be achieved with utilizing gentle lotions, creams, and/or occlusives to restore the skin barrier. Eliminating harsh skin regimens or products will be necessary to minimize potential for further purpura or trauma, skin sensitivity, and potential infection.

Alternative treatment

Development of alternative treatment with less side effects are available. This secondary treatment may also be considered if treatment of the skin condition is refractory to topical steroids. Other treatment choices will depend on the skin condition being treated.

Atopic Dermatitis

Topical steroids are the primary treatment of choice for atopic dermatitis. However, topical immunomodulators (tacrolimus, pimecrolimus) and biologics are available options. The mechanism of these alternatives target a different pathway than topical steroids, which help reduce side effects.

Psoriasis

Topical treatment with steroids are effective in most cases of mild psoriasis. In cases refractory to topical steroids or in the presence of steroid side effects, topical vitamin D anologues (calcipotriol, calcipotriene) have shown to be effective. Off-label use of topical calcineurin inhibitors (tacrolimus, pimecrolimus) is also available with lesser known efficacy.

Prognosis

Steroid-induced skin atrophy is often permanent, though if caught soon enough and the topical corticosteroid discontinued in time, the degree of damage may be arrested or slightly improve. If cessation of topical steroid occurs while side effects are only at the level of the epidermis, these effects can be reversible. Deeper dermal damage is often irreversible. Dermal damage is typically marked by telangiectasias and stretch marks. However, while the accompanying telangiectasias may improve marginally, the stretch marks are permanent and irreversible.

Exacerbating factors

Common factors that increase the risk of skin thinning with steroid use include the following:

1. Applying too much steroid to the area of treatment
2. Using topical steroids for extended periods (14–21 days)
3. Applying topical steroids to intertriginous areas such as the armpits, under the breasts, or on the groin
4. Using occlusive dressings, such as bandages, band aids, and clothing
5. Age (infancy/childhood, elderly)

Prevention

Finger-tip unit

Education on proper application and signs of steroid side effects are important in preventing permanent side effects. The fingertip unit (FTU) is a concept used to standardize amount of steroid applied per area of affected skin. One FTU is approximately 0.5 grams of medication that covers 2% of body surface area. It is defined as the amount of medication dispensed from the tip of the finger to the distal interphalangeal joint. Recommended FTU in a single application is determined by location of affected skin. The face and neck requires 2.5 fingertip units, the front trunk 7 fingertip units, the back trunk 7 fingertip units, one arm 3 fingertip units, one hand (front and back) 1 fingertip unit, one leg 6 fingertip units, and one foot 2 fingertip units.

Caution with high-potency steroid application

Strong steroids should be avoided on sensitive sites such as the face, inframammary folds, groin, and armpits. Application of weak steroids to these areas should be limited to less than two weeks of continuous use. In general, use a potent preparation short term and weaker preparation for maintenance between flare-ups.

Pulse therapy

While there is no proven best benefit-to-risk ratio, if prolonged use of a topical steroid is required, pulse therapy can be used as a mechanism to prevent side effects. Pulse therapy refers to the application of a corticosteroid for 2 or 3 consecutive days each week or two. This is useful for maintaining control of chronic diseases. Generally a milder topical steroid or non-steroid treatment is used on the in-between days.

Weekend treatment in atopic dermatitis

For treating atopic dermatitis, newer (second generation) corticosteroids, such as fluticasone propionate and mometasone furoate, are more effective and safer than older steroid generations. They are also generally safe and do not cause skin thinning when used intermittently to treat atopic dermatitis flare-ups. They are also safe when used twice a week for preventing flares (also known as weekend treatment). Applying once daily is enough as it is as effective as twice or more daily application.

Mechanism of action

Steroids have anti-inflammatory, anti-proliferative, and immunosuppressive effects that make it the mainstay of treatment for autoimmune and inflammatory conditions such as psoriasis and atopic dermatitis. Steroids bind intracellularly to their receptors found in the epidermis and dermis. Recent research has found transactivation of these receptors as a mechanism for steroid atrophy. Further research has shown the pathogenesis of skin atrophy is due to its inhibitory effects on key skin components at different levels of the skin. Keratinocyte proliferation is inhibited in the epidermis, while collagen 1 and 3 synthesis is halted at the dermis. Dermal atrophy intensifies with cessation of fibroblasts and hyaluronan synthase 3 enzyme leads because of decreased hyaluronic acid. Atrophic effects begin within 3–14 days of consistent topical steroid use and is first evident in the epidermal layer. Symptoms occurring at the level of epidermis are reversible. Prolonged use compromises the skin barrier integrity, which can cause dermal (more permanent) effects.

Topical Steroid Classes

The strength of topical steroids is an important consideration in choosing a steroid to prescribe. Topical steroids are divided into classes based on potency. Low potency steroids (hydrocortisone, triamcinolone acetonide) may be used on any surface of the body and for a longer period (typically 1–2 weeks). Higher potency steroids (clobetasol, betamethasone) are reserved for severe pruritus that has been refractory to lower potency topical steroids. Higher potency steroids are used for a shorter periods to control exacerbations.

References

NOTOC

References

1. (November 2004). "Dermoscopic assessment of long-term topical therapies with potent steroids in chronic psoriasis". Journal of the American Academy of Dermatology.
2. (2021). "Comprehensive Dermatologic Drug Therapy".
3. (1988). "Side effects of topical corticosteroids and their prevention". Drugs.
4. (1995). "Skin atrophy induced by initial continuous topical application of clobetasol followed by intermittent application". Dermatology.
5. (January 2006). "Adverse effects of topical glucocorticosteroids". Journal of the American Academy of Dermatology.
6. (January 2009). "Choosing topical corticosteroids". American Family Physician.
7. (May 2012). "Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy". Journal of the European Academy of Dermatology and Venereology.
8. (October 2023). "The long-term safety of topical corticosteroids in atopic dermatitis: A systematic review". Skin Health and Disease.
9. (December 2023). "Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials". The Journal of Allergy and Clinical Immunology.
10. (July 2021). "Safety of topical corticosteroids in atopic eczema: an umbrella review". BMJ Open.
11. (September 2014). "Topical steroid-damaged skin". Indian Journal of Dermatology.
12. (March 2021). "Topical Corticosteroids: Choice and Application". American Family Physician.
13. (October 2014). "Side-effects of topical steroids: A long overdue revisit". Indian Dermatology Online Journal.
14. Atherton, David J.. (2003-10-25). "Topical corticosteroids in atopic dermatitis". BMJ (Clinical Research Ed.).
15. (October 2021). "The New Era of Biologics in Atopic Dermatitis: A Review". Dermatology Practical & Conceptual.
16. (2021-04-27). "Psoriasis: Learn More – Skin care and topical treatments". Institute for Quality and Efficiency in Health Care (IQWiG).
17. (September 2014). "Topical steroid-damaged skin". Indian Journal of Dermatology.
18. (2020-08-12). "Mind the Gap: A handbook of clinical signs in Black and Brown skin".
19. (2000). "Color Atlas of Steroid Withdrawal from Corticosteroids in Patients with Atopic Dermatitis". Ishiyaku Publishers, Inc..
20. (June 2000). "Atopic Dermatitis and Steroid Withdrawal". Ishiyaku Pub, Inc..
21. "Steroid Atrophy".
22. (2022). "Standardization of topical preparations for finger-tip unit—Awareness and attitudes among pharmacists and dermatologists and suggestions to improve standardization of topical drug dosing—A two-phase cross-sectional survey". Journal of Cosmetic Dermatology.
23. (January 2009). "Choosing topical corticosteroids". American Family Physician.
24. (3 March 2024). "Course on topical steroids".
25. (March 2022). "Strategies for using topical corticosteroids in children and adults with eczema". The Cochrane Database of Systematic Reviews.
26. (2020-12-30). "Glucocorticoid-Induced Skin Atrophy: The Old and the New". Clinical, Cosmetic and Investigational Dermatology.